A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Phase
3Span
494 weeksSponsor
Eli Lilly and CompanyTosno
Recruiting
1-1 of 1